

# MEDICATION COVERAGE POLICY

## PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE

<b>POLICY:</b>	Psoriatic Arthritis (PsA)	<b>P&amp;T DATE</b>	7/12/2022
<b>CLASS:</b>	Rheumatology/Immunology Disorders	<b>REVIEW HISTORY</b>	5/21, 5/20, 5/19, 2/18, 2/17, 2/16, 5/15, 10/14, 2/13, 2/12, 11/12, 5/10, 2/08, 6/08, 2/07
<b>LOB:</b>	MCL		

*This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the HPSJ Pharmacy and Therapeutic Advisory Committee.*

Effective 1/1/2022, the Pharmacy Benefit is regulated by Medi-Cal Rx. Please visit <https://medi-calrx.dhcs.ca.gov/home/> for portal access, formulary details, pharmacy network information, and updates to the pharmacy benefit.

All medical claims require that an NDC is also submitted with the claim. If a physician administered medication has a specific assigned CPT code, that code must be billed with the correlating NDC. If there is not a specific CPT code available for a physician administered medication, the use of unclassified CPT codes is appropriate when billed with the correlating NDC.

## OVERVIEW

Psoriatic arthritis (PsA) is an inflammatory condition that usually involves small joints and skin. Individuals with PsA exhibit both arthritis and psoriasis (PsO) symptoms (i.e. joint pain/stiffness, joint swelling, psoriatic plaque development, and/or nail disfiguration). This review will examine the treatment guidelines of PsA, the currently available PsA drug products, and their coverage criteria.

Severe Psoriatic Arthritis*	Severe Psoriasis*
Erosive disease	Psoriasis area & Severity Index (PASI) $\geq 12$
Elevated markers of inflammation (ESR, CRP)	Body surface area (BSA) $\geq 10$
Long-term damage that interferes with function and causing major impairment in quality of life	Significant involvement in specific areas (e.g. face, hands or feet, nails intertriginous areas, scalp)
Many affected sites including dactylitis, enthesitis	Burden of the disease causing significant disability
Function-limiting PsA at a few sites, rapidly progressive disease	Impairment of physical or mental function and the designation of moderate-to-severe disease despite lower BSA

\*The definition of severe PsA and psoriasis as the presence of 1 or more of the items listed. This is not a formal definition. Table adapted from the 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

### Available Psoriatic Arthritis Agents (Current as of 4/2022)

Class	Drug	CPT Code	Available Strengths	Pharmacy Benefit	Medical Benefit	Notes
Oral DMARDS	Cyclosporine, micronized	--	25 mg, 100 mg capsule	Yes	No	
	Leflunomide (Arava)	--	10 mg tablet	Yes	No	
	Methotrexate Tablet, vial	J8610 J9260	2.5 mg, 25 mg/2ml	Yes	Yes	J9260 auth not required office based. Quantity limit 4 units per 28 days.
	Sulfasalazine Tablet, DR Tablet	--	500 mg	Yes	No	
PDE-4 Inhibitor	Apremilast (Otezla)	--	30 mg	Yes	No	

<b>Biologics</b>	Adalimumab (Humira, Humira CF)	J0135	20mg/0.4ml, 40mg/0.8ml 40mg/0.4ml	Yes	No	Reserved for treatment failure to infliximab-abda, infliximab-dyyb, golimumab, certolizumab, ustekinumab, ixekizumab, or abatacept.
	Etanercept (Enbrel)	J1438	25mg/ml, 50mg/ml	Yes	No	Reserved for treatment failure to infliximab-abda, infliximab-dyyb, golimumab, certolizumab, ustekinumab, ixekizumab, or abatacept.
	Infliximab-dyyb (Inflectra) Infliximab-abda (Renflexis)	Q5103/ Q5104	100mg IV vial	Yes	Yes	Reserved for treatment failure to one oral DMARD for 3 months.
	Infliximab (Remicade)	J1745	100mg IV vial	Yes	Yes	Non-Formulary
	Infliximab-axxq (Avsola)	Q5121	100mg IV vial	Yes	Yes	Non-Formulary
	Abatacept (Orencia)	J0129	125mg/ml clickjet; 50mg/0.4mL, 87.5mg/0.7ml, 125mg/ml prefilled syringe; 250mg IV vial	Yes	Yes (vial for IV infusion only)	Reserved for treatment failure to one oral DMARD for 3 months.
	Certolizumab (Cimzia)	J0717	200mg	Yes	No	Reserved for treatment failure to one oral DMARD for 3 months.
	Golimumab (Simponi)	J1602	50mg/4ml IV vial, 100mg/ml, 50mg/0.5ml auto-injector, 50mg/0.5ml 100mg/ml prefilled syringe	Yes	Yes (vial for IV infusion only)	Reserved for treatment failure to one oral DMARD for 3 months.
	Secukinumab (Cosentyx)	--	150mg/ml	Yes	No	Reserved for treatment failure to infliximab-abda, infliximab-dyyb, golimumab, certolizumab, ustekinumab, ixekizumab, or abatacept.
Guselkumab (Tremfya)	J1628	100mg/mL	Yes	No	Reserved for treatment failure to infliximab-abda, infliximab-dyyb, golimumab, certolizumab, ustekinumab, ixekizumab, or abatacept.	

	Ixekizumab (Taltz)	--	80mg/ml	Yes	No	Reserved for treatment failure to one oral DMARD for 3 months.
	Ustekinumab (Stelara)	J3357	45mg/0.5ml, 90mg/ml	Yes	No	Reserved for treatment failure to one oral DMARD for 3 months.
	Risankizumab (Skyrizi)	--	150mg pre-filled syringe kit 150mg/mL auto-injector	Yes	No	Reserved for treatment failure to infliximab-abda, infliximab-dyyb, golimumab, certolizumab, ustekinumab, ixekizumab, or abatacept.
<b>JAK-Inhibitor</b>	Tofacitinib (Xeljanz, Xeljanz XR)	--	IR: 5mg, XR: 10mg	Yes	No	
	Upadacitinib (Rinvoq)	--	15mg	Yes	No	

## ⊕ EVALUATION CRITERIA FOR APPROVAL/EXCEPTION CONSIDERATION

Below are the coverage criteria and required information for each agent. These coverage criteria have been reviewed approved by the HPSJ Pharmacy & Therapeutics (P&T) Advisory Committee. For conditions not covered under this Coverage Policy, HPSJ will make the determination based on Medical Necessity as described in HPSJ Medical Review Guidelines (UM06).

### Biologics

**1<sup>st</sup> line— Renflexis (infliximab-abda), Inflectra (infliximab-dyyb), Simponi (golimumab), Cimzia (certolizumab), Stelara (ustekinumab), Taltz (ixekizumab), Orencia (abatacept)**

- Coverage Criteria:** Reserved for treatment failure to 12 weeks of dose-optimized, oral DMARD therapy (Methotrexate 15-25mg/week, Cyclosporine, Sulfasalazine, and Leflunomide). If patient is unable to tolerate one oral DMARD, a second oral DMARD must be tried. Must be prescribed by a rheumatologist or dermatologist.
- Limits:** None
- Required Information for Approval:** Clinic notes or prescription history indicating patient has tried at least 12 weeks of dose-optimized oral DMARD (Methotrexate, Cyclosporine, Sulfasalazine, and Leflunomide).

**2<sup>nd</sup> line— Humira (adalimumab), Enbrel (etanercept), Cosentyx (secukinumab), Tremfya (guselkumab), Skyrizi (risankizumab)**

- Coverage Criteria:** Reserved for treatment failure/documented intolerance to Renflexis, Inflectra, Simponi, Cimzia, Stelara, Taltz, or Orencia. Must be prescribed by a rheumatologist or dermatologist.
- Limits:** None
- Required Information for Approval:** Prescription history of Renflexis, Inflectra, Simponi, Cimzia, Stelara, Taltz, or Orencia.

## ⊞ **CLINICAL JUSTIFICATION**

### *Psoriatic Arthritis*

2018 The American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) Guideline for the Treatment of Psoriatic Arthritis<sup>39</sup>

#### Highlights

- Most recommendations are conditional and applies to the majority of patients but may not be appropriate for all (shared decision-approach).
- Strong recommendations for patients with active PsA and concomitant active inflammatory bowel disease despite treatment with an oral small molecule (e.g. methotrexate)
  - Switch to a TNFi monoclonal antibody biologic over switching to a TNFi biologic soluble receptor biologic (i.e. etanercept).
  - Switch to a TNFi monoclonal antibody over switching to an interleukin (IL)-17 biologic
  - Switch to an IL-12/IL-23i biologic over switching to an IL-17i biologic.
- Other strong recommendations:
  - In adult patients with active PsA and frequent serious infections who are naïve to oral small molecule (OSM) and biologic drugs may start an oral small molecule over a TNFi biologic.
  - Smoking cessation over no smoking cessation.
- Conditional Recommendations
  - Treat-to-target approach for all patients with active PsA.
  - For treatment naïve, active PsA patients- use TNFi biologics as first-line therapy over OSM/DMARDs.
  - OSM drugs may be used instead of a TNFi biologic in patients without severe PsA and without severe psoriasis or in those who prefer an oral drug instead of parenteral therapy, or those with contraindications to TNFi treatment (congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease).
  - For treatment-naïve patients with active PsA, the use of TNFi biologic or OSM is recommended over an interleukin-17.
  - An IL-17i or IL-12/23i may be used instead of TNFi biologics with severe psoriasis or contraindications to TNF biologics.
  - In patients with active PsA despite OSM therapy, switching to a TNFi, IL-17i, or an IL-12/23i biologic is recommended over switching to a different OSM. A different OSM may be used rather than a TNFi, IL17i, or IL-12/23i in patients who prefer an oral medication or those without evidence of severe PsA or severe psoriasis.
  - In patients with active PsA despite TNFi treatment, switching to a different TNFi biologic monotherapy is recommended over switching to IL-12/23i biologic, IL-17i biologic, abatacept, or tofacitinib monotherapy or adding methotrexate to the current TNFi biologic. An IL-12/23i biologic, IL-17i biologic, abatacept, or tofacitinib may be used instead of a different TNFi biologic monotherapy in the case of a primary TNFi biologic failure or serious adverse event to a TNFi.
  - An IL-17i or IL-12/23i biologic may be used instead of a different TNFi biologic, particularly in the presence of severe psoriasis. Abatacept may be used instead of a TNFi biologic in patients with recurrent or serious infections in the absence of severe psoriasis.
  - In treatment-naïve PsA patients with predominant enthesitis, a TNFi biologic is recommended over an OSM as a first-line option.
- The recommendation to use biologics as first-line treatment diverges from recommendations by the European League for Rheumatism (EULAR) for PsA where oral small molecules drugs are recommended as first-line agents for treatment-naïve patients. This was in part due to the lower

cost of conventional oral small molecules agents. However, because the ACR/NPF guidelines note that this is a conditional recommendation due to low-to very-low quality evidence, HPSJ will continue to use oral small molecule drugs as first-line agents from a cost effective standpoint. HPSJ will take into consideration with the use of TNF-inhibitors as first line treatments in patients with predominant enthesitis or severe PsA.


The 2019 EULAR PsA Guidelines<sup>46</sup> recommends the following:

	Recommendations	Level of evidence	Grade of recommendation	Level of agreement, mean (SD)
1	Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.	1b	A	9.4 (1.0)
2	Non-steroidal anti-inflammatory drugs may be used to relieve musculoskeletal signs and symptoms.	1b	A	9.6 (0.8)
3	Local injections of glucocorticoids should be considered as adjunctive therapy in psoriatic arthritis*; systemic glucocorticoids may be used with caution at the lowest effective dose†.	3b* 4†	C	9.5 (1.1)
4	In patients with polyarthritis, a csDMARD should be initiated* rapidly†, with methotrexate preferred in those with relevant skin involvement*.	1b* 5†	B	9.5 (0.8)
5	In patients with monoarthritis or oligoarthritis, particularly with poor prognostic factors such as structural damage, high erythrocyte sedimentation rate/C reactive protein, dactylitis or nail involvement, a csDMARD should be considered.	4	C	9.3 (1.0)
6	In patients with peripheral arthritis and an inadequate response to at least one csDMARD, therapy with a bDMARD should be commenced; when there is relevant skin involvement, an IL-17 inhibitor or IL-12/23 inhibitor may be preferred.	1b	B	9.4 (1.1)
7	In patients with peripheral arthritis and an inadequate response to at least one csDMARD and at least one bDMARD, or when a bDMARD is not appropriate, a JAK inhibitor may be considered.	1b	B	9.2 (1.3)
8	In patients with mild disease* and an inadequate response to at least one csDMARD†, in whom neither a bDMARD nor a JAK inhibitor is appropriate*, a PDE4 inhibitor may be considered.	5* 1b†	B	8.5 (1.9)
9	In patients with unequivocal enthesitis and insufficient response to NSAIDs or local glucocorticoid injections, therapy with a bDMARD should be considered.	1b	B	9.3 (0.9)
10	In patients with predominantly axial disease which is active and has insufficient response to NSAIDs, therapy with a bDMARD should be considered, which according to current practice is a TNF inhibitor; when there is relevant skin involvement, IL-17 inhibitor may be preferred.	1b	B	9.7 (0.6)
11	In patients who fail to respond adequately to, or are intolerant of a bDMARD, switching to another bDMARD or tsDMARD should be considered*, including one switch within a class†.	1b* 4†	C	9.5 (1.2)
12	In patients in sustained remission, cautious tapering of DMARDs may be considered.	4	C	9.5 (0.9)

The level of agreement was computed on a 0–10 scale.

csDMARDs include methotrexate, sulfasalazine or leflunomide; bDMARDs include here TNF inhibitors (both original and biosimilars) and drugs targeting the IL-17 and IL-12/23 pathways.

bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DMARDs, disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; IL, interleukin; JAK, Janus kinase; NSAIDs, non-steroidal anti-inflammatory drugs; PDE4, phosphodiesterase-4; TNF, tumour necrosis factor.



1. No glucocorticoids for axial disease.

2. The target is remission or low disease activity (especially with long standing disease) in accordance with the treat-to-target recommendations.

3. Preferred in the presence of relevant skin involvement, however in case of concomitant inflammatory bowel disease or uveitis, an anti-TNF antibody would be preferred.

4. Improvement means at least 50% reduction in disease activity.

5. As add-on to methotrexate.

6. Consider cautious tapering in sustained remission.

7. Including abatacept.

8. For definition of individual items see text. Phase I: recommendations 1, 2, 3, 4, 5; Phase II: recommendations 1, 3, 4, 5, 12; Phase III: recommendations 6, 8, 9, 10, 12; Phase IV: recommendations 7, 11, 12.

### Highlights

- The 2019 EULAR Guidelines recommend a “treat-to-target” approach for PsA.
  - Patients with active disease should be monitored every 3 months and treatment should be adjusted when appropriate. The TICOPA trial demonstrated patients who had treatment escalation from DMARD therapy to biologics had better therapeutic outcomes when they were monitored and the treatment regimen was adjusted more vigorously.<sup>3</sup>
- In patients with polyarthritis, a csDMARD (methotrexate, sulfasalazine, or leflunomide) should be considered first, with methotrexate preferred in those with relevant skin involvement.<sup>4</sup>
- Patients with monoarthritis or oligoarthritis, particularly with poor prognostic factors such as structural damage, high erythrocyte sedimentation rate/C reactive protein, dactylitis or nail involvement, a csDMARD should be considered.
- Patients with peripheral arthritis and an inadequate response to at least one csDMARD, can consider therapy with a bDMARD (TNF, IL-12/23, or IL-17 inhibitor). When there is relevant skin involvement, an IL-17 inhibitor or IL-12/23 inhibitor may be preferred.
- Patients with peripheral arthritis and an inadequate response to at least one csDMARD and at least one bDMARD, or when a bDMARD is not appropriate, a JAK inhibitor may be considered.
- In patients with mild disease and an inadequate response to at least one csDMARD, in whom neither a bDMARD nor a JAK inhibitor is appropriate, a PDE4 inhibitor may be considered.
- Patients with predominantly axial disease that is active and has insufficient response to NSAIDs, biologics should be considered, which according to current practice is a TNF inhibitor. When there is relevant skin involvement an IL-17 inhibitor may be preferred.

The 2019 EULAR guidelines recommends for patients with polyarthritis that a csDMARD (methotrexate, sulfasalazine, or leflunomide) is initiated first. Only in patients with an inadequate response to at least one csDMARD do they recommend therapy with a bDMARD instead. On the other hand, the 2018 ACR guidelines recommend TNF inhibitors as first line, followed by IL-17 inhibitors and then IL-12/23 inhibitors. However, the 2018 ACR guidelines do recommend csDMARD’s as first line therapy like the EULAR guidelines in specific instances. These instances include if the patient does not have severe PsA, does not have severe psoriasis, prefers oral therapy, has concern over starting a biologic as the first therapy, or has contraindications to TNFi biologics. Therefore, our HPSJ criteria generally requires initiating therapy with oral DMARDs prior to biologics and allowing some exceptions upon review. Efficacy between biologics does not differ significantly, but the cost may vary due to differences in administration frequency (twice monthly vs. weekly vs. monthly, and so forth). Therefore, HPSJ’s order of preference of the biologic therapies are based on the cost-benefit ratio where the first-line biologics are agents associated with the lowest cost-benefit ratio.

### ***Role of oral agents (DMARDs and immunosuppressants)***

Oral DMARDs are commonly used as first-line therapies in many mild-moderate inflammatory disorders with a few exceptions (e.g. Ankylosing Spondylitis). For most patients, treatment with oral agents may be sufficient for their condition. Generally, 12 weeks of continuous DMARD therapy is considered to be an adequate trial—assuming the drug is adequately dosed. In patients with liver and/or renal impairment, DMARDs are not necessarily excluded right away. In most cases, DMARDs can be safely used as long as there is regular monitoring of labs and side effects and the dosing is adjusted accordingly.

Table 1: Commonly used oral agents in chronic inflammatory diseases

Oral Agent	Joint	Skin	GI	liver damage	kidney damage	Pregnancy	Breastfeeding
<b>Azathioprine</b>	X	X*	X	monitor	monitor & dose adjust	Avoid use	Not recommended
<b>Cyclosporine</b>	X*	X	X*	monitor	monitor & dose adjust	Avoid use	Not recommended
<b>Leflunomide</b>	X	X	X*	avoid use	avoid use	Contraindicated	Unknown
<b>Mercaptopurine</b>	X*	X*	X	monitor	monitor & dose adjust	Avoid use	Unknown
<b>Methotrexate</b>	X	X	X	avoid use	monitor & dose adjust	Contraindicated	Contraindicated
<b>Sulfasalazine</b>	X	X*	X	monitor	monitor	Generally safe	Generally safe

*\*limited evidence*

### Special Populations

#### Pregnancy

Guidelines for pregnancy, as stated by the Canadian guidelines and the American National Psoriasis Foundation, indicate that 1<sup>st</sup> line therapy includes low- to moderate potency corticosteroids, 2<sup>nd</sup> line therapy includes narrow band UVB, and 3<sup>rd</sup> line therapy, only to be used if benefits outweigh risks, includes cyclosporine or TNF inhibitors.<sup>20-21</sup> Other DMARDs deemed safe include sulfasalazine and azathioprine, and possibly leflunomide.<sup>22</sup> Azathioprine has a risk for premature births and, although limited animal data contraindicates its use, leflunomide has an apparently low human teratogenicity risk. Cyclosporine and sulfasalazine seem to be the safest or most preferred DMARD agents.<sup>22</sup>

#### Elevated LFTs

Specific guidelines for patients who have elevated LFTs are not available, but the American Academy of Dermatology guidelines do have suggestions for LFT monitoring and some recommendations on protocol if LFTs are elevated to a certain level. For methotrexate, if elevation exceeds 2x normal levels, LFT monitoring must be checked more frequently; if elevation exceeds 3x normal levels, consider dose reduction (administer 75% of dose); if elevation exceeds 5x normal, discontinuation of the medication is recommended. No other drugs have specific guidelines for LFT levels.<sup>23</sup> The 2008 ACR guidelines state that leflunomide, methotrexate, and sulfasalazine should not be started nor resumed if liver transaminases were >2x the upper normal limit. Despite this, there are no recommendations on discontinuation.<sup>24</sup> A paper regarding expert opinion on the treatment of psoriasis in special circumstances speaks to the use of biologics in the setting of fatty liver disease. The panel considered etanercept and ustekizumab to be the best options for use in a patient with fatty liver disease.<sup>25</sup>



## ☒ REFERENCES

1. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*. 2015; doi:10.1136/annrheumdis-2015-208337.
2. Singh JA, Saag KG, Bridges JR L, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research*. 2015; DOI 10.1002/acr.22783.
3. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomized controlled trial. *Lancet* 2015 doi: 10.1016/S0140-6736(15)00347-5.
4. Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. *Br J Dermatol* 2014;170:274–303.
5. Coates LC, Tillett W, Chandler D, et al. The 2012 BSA and BHPR guideline for the treatment of psoriatic arthritis with biologics. *Rheumatology*. 2013. doi: 10.1093/rheumatology/ket187.
6. Gottlieb A, Korman N, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2—Psoriatic Arthritis: Overview and guidelines of care for treatment with an emphasis on biologics. *J Am Acad Dermatol*. 2008; 58: 851-64.
7. Ramiro S, Smolen SJ, Landewe Ro, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*. December 2015. doi:10.1136/annrheumdis-2015-208466.
8. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. *Arthritis Res Ther* 2016;18:82.
9. ClinicalTrials.Gov. Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis. October 23, 2016. <https://clinicaltrials.gov/ct2/show/NCT01970475>. Accessed January 22, 2017.
10. Griffiths CE, et al. The EGALITY study: A confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. *Br J Dermatol*. 2016 Oct 27. doi: 10.1111/bjd.15152.
11. Dapavo P, et al. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. *Journal of American Academy of Dermatology*. 2016 Oct;75(4):736-9.
12. FIMEA. Interchangeability of Biosimilars—Position of Finnish Medicines Agency Fimea. May 22, 2015. [http://www.fimea.fi/instancedata/prime\\_product\\_julkaisu/fimea/embeds/fimeawwwstructure/29197\\_Biosimilaarien\\_vaihtokelpoisuus\\_EN.pdf](http://www.fimea.fi/instancedata/prime_product_julkaisu/fimea/embeds/fimeawwwstructure/29197_Biosimilaarien_vaihtokelpoisuus_EN.pdf). Accessed January 22, 2017.
13. FDA. Summary Minutes of the Arthritis Advisory Committee Meeting. July 12, 2016. <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM520027.pdf>. Accessed January 21, 2017.
14. Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis* 2016; 75:974–82. doi:10.1136/annrheumdis-2016-209166
15. FDA. Biosimilars: Questions and Answers Regarding implementation of Biologics Price Competition and Innovation Act of 2009. April 2015. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf>. Accessed January 21, 2017
16. Dapavo P, et al. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. *Journal of American Academy of Dermatology*. 2016 Oct;75(4):736-9
17. Results from the NOR-SWITCH study support switch from Remicade to Remsima (biosimilar infliximab). Mundipharma. 19 October 2016. <http://www.mundipharma.com/docs/default->

source/default-document-library/161019-ueg-press-release-final.pdf?sfvrsn=0. Accessed 2 Feb 2017.

18. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. *N Engl J Med*. 2015;373(14):1329-39.
19. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015;386(9999):1137-46.
20. Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. *J Cutan Med Surg*. 2016 Sep;20(5):375-431.
21. Bangsgaard N, et al. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. *Am J Clin Dermatol*. 2015. 16:389-398.
22. Kurizky PS, et al. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding. *An Bras Dermatol*. 2015;90(3):367-75.
23. Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. 2009 Sep; 61(3): 451-485.
24. Saag KG, et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. 2008 Jun 15; 59(6):762-784.
25. Carrascosa JM, et al. Expert Recommendations on Treating Psoriasis in Special Circumstances. 2015 April. 106(4):292-309.
26. San Joaquin County. United States Census Bureau website. <https://www.census.gov/quickfacts/sanjoaquincountycalifornia>. Updated 2019. Accessed May 4<sup>th</sup>, 2022.
27. Stanislaus County. United States Census Bureau website. <https://www.census.gov/quickfacts/fact/table/stanislauscountycalifornia/PST045221>. Updated 2019. Accessed May 4<sup>th</sup>, 2022.
28. Health Plan of San Joaquin. *Medication Coverage Policy Psoriasis*. French Camp, CA: Health Plan of San Joaquin; 2022.
29. Body Measurements. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nchs/fastats/body-measurements.htm>. Updated September 10, 2021. Accessed May 4<sup>th</sup>, 2022.
30. Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. *Arch Dermatol*. 2010;146(7):721-726.
31. Obesity and Socioeconomic Status in Adults. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nchs/products/databriefs/db50.htm>. Updated November 6, 2015. Accessed May 5<sup>th</sup>, 2022.
32. Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. *Health Technology Assessment*. 2011; 15(10). DOI: 10.3310/hta15100.
33. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). *Ann Rheum Dis*. 2014; 73(1): 48-55.
34. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic and safety results from a phase III, randomized, placebo-controlled trial. *Arthritis Rheum*. 2012; 64(8): 2504-17.
35. Ramiro S, Smolen SJ, Landewe Ro, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*. December 2015. doi:10.1136/annrheumdis-2015-208466.

36. Prescribing information: Orencia®. Princeton, NJ; Bristol-Meyers Squibb Company.
37. van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1) [published online December 15, 2017]. *J Rheumatol*. doi:10.3899/jrheum.170429
38. Prescribing information: Taltz. Indianapolis, Indiana; Eli Lilly and Company
39. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheumatol*. 2018; 71 (1): 5-32.
40. Prescribing information: Xeljanz and Xeljanz XR® NY, NY; Pfizer Labs.
41. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. *N Engl J Med*. 2017; 377:1537-1550.
42. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. *N Engl J Med*. 2017; 377: 1525-1536.
43. ClinicalTrials.gov [Internet]. Identifier: NCT01976364, Open-Label Extension Study of Tofacitinib in Psoriatic Arthritis. Available from: <https://clinicaltrials.gov/ct2/show/NCT01976364>.
44. Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF $\alpha$  inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2020;395(10230):1115-1125.
45. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2020;395(10230):1126-1136.
46. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*. 2020;79(6):700-712.
47. Smolen J, Siebert S, Korotaeva T, et al. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. *Ann Rheum Dis*. 2021;80(11):1419-1428.
48. Mease P, Gottlieb A, Van Der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomized, double-blind, placebo-controlled, phase III study in psoriatic arthritis. *Ann Rheum Dis*. 2017;76(9):1550-1558.
49. Mease P, McInnes I, Tam L, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. *Rheumatology (Oxford, England)*. 2021;60(50):2109-2121.

## **REVIEW & EDIT HISTORY**

Document Changes	Reference	Date	P&T Chairman
Creation of Policy	Psoriasis - biologicals 2-20-07.doc	2/2007	Allen Shek, PharmD
Updated Policy	Biological Response Modifiers Review 2-19-08.doc	2/2008	Allen Shek, PharmD
Updated Policy	HPA Suppression among Medium Potency Topical Corticosteroids.doc	6/2008	Allen Shek, PharmD
Updated Policy	Biologic Response Modifiers 2010 final.docx	5/2010	Allen Shek, PharmD
Updated Policy	TNF MUE summary 2-21-2012.docx	2/2012	Allen Shek, PharmD
Updated Policy	Calcipotriene.docx	11/2012	Allen Shek, PharmD
Updated Policy	Biologic Response Modifiers for Psoriasis 2013-2-19.docx	2/2013	Allen Shek, PharmD
Updated Policy	Psoriatic Arthritis & Ankylosing Spondylitis.docx	10/2014	Jonathan Szkotak, PharmD
Updated Policy	Class Review of Topical & Systemic Agents Used for Skin Inflammation Disorders with an Emphasis on Psoriasis.docx	5/2015	Jonathan Szkotak, PharmD

Updated Policy	HPSJ Coverage Policy – Rheum & immuno – Psoriatic Arthritis 2015-05.docx	9/2015	Jonathan Szkotak, PharmD
Updated Policy	Class Review- Biologics, Apremilast, and Tofacitinib in Inflammatory Joint, Skin, and Bowel Diseases.docx	2/2016	Johnathan Yeh, PharmD
Updated Policy	HPSJ Coverage Policy - Rheum & Immuno - Psoriatic Arthritis 2017-02.docx	2/2017	Johnathan Yeh, PharmD
Updated Policy	HPSJ Coverage Policy - Rheum & Immuno - Psoriatic Arthritis 2018-02.docx	02/2018	Johnathan Yeh, PharmD
Updated Policy	HPSJ Coverage Policy - Rheum & Immuno - Psoriatic Arthritis 2019-05.docx	05/2019	Matthew Garrett, Pharm D
Updated Policy	Psoriatic Arthritis 2020-05.docx	05/2020	Matthew Garrett, Pharm D
Updated Policy	Psoriatic Arthritis.docx	05/2021	Matthew Garrett, Pharm D
Updated Policy	Psoriatic Arthritis.docx	07/2022	Matthew Garrett, Pharm D

*Note: All changes are approved by the HPSJ P&T Committee before incorporation into the utilization policy*